[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fuchs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fuchs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100460465","phase-3-descemet-endothelial-thickness-comparison-trial-ii-100460465",false,"NCT05275972","Descemet Endothelial Thickness Comparison Trial II","Descemet Endothelial Thickness Comparison Trials (DETECT I & II)","DETECT II","Inclusion Criteria:\n\n* Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm\n* Peripheral endothelial cell count \\>1000 cells\u002Fmm2 in at least one quadrant\n* Good surgical candidate for either procedure as determined by the surgeon\n* Willingness to participate\n* Age greater than 18 years\n\nExclusion Criteria:\n\n* Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK\n* Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment\n* Other primary endothelial dysfunction such as PPMD\n* Visually significant optic nerve or macular pathology\n* Hypotony (Intraocular pressure \\\u003C10mmHg)\n* Any prior intraocular surgery other than cataract surgery\n* \\>3 clock hours of ANY anterior or posterior synechiae\n* \\>1 quadrant of stromal corneal vascularization\n* Inability to comply with post-operative instructions (i.e. unable to position)\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.",[27,28,29],"Fuchs","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","RECRUITING","2026-08-13",{"date":33,"type":34},"2026-08-17","ACTUAL",{"date":36,"type":34},"2023-01-23",{"date":38,"type":21},"2028-10-30",{"name":40,"class":41},"Stanford University","OTHER",8,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100649041","phase-2-study-of-eo2002-in-subjects-with-corneal-edema-secondary-to-corneal-endothelial-dysfunction-100649041","NCT07729137","Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction","A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)","EMERALD","Key Inclusion Criteria:\n\n1. Symptomatic central corneal edema that is primarily responsible for loss of vision associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.\n2. Early Treatment Diabetic Retinopathy Study (ETDRS)-best-corrected distance visual acuity between 20 and 65 letters inclusive (≥ 20 and ≤ 65 letters)\n3. Central corneal thickness ≥ 600 μm and ≤ 1,000 μm, OR Medical Monitor review and approval based on either:\n\n   1. Historical CCT increased by ≥ 50 μm OR\n   2. Findings of edema by corneal tomography or Anterior Segment Optical Coherence Tomography (AS-OCT).\n4. Participant is considered a surgical candidate for full-thickness corneal transplantation or endothelial (partial thickness) keratoplasty (EK) consistent with standard-of-care indications.\n\nKey Exclusion Criteria:\n\n1. Corneal disease in either eye (other than corneal endothelial dysfunction secondary to Fuchs dystrophy or pseudophakic bullous keratopathy) including active or prior herpetic ocular infection, severe dry eye disease (e.g., Sjogren's), or active inflammation.\n2. Central corneal scarring from trauma, burns, or infection, or band keratopathy\n3. History of keratoconus or other corneal ectasia (e.g., keratoglobus and pellucid marginal degeneration).\n4. Visually significant cataract, that may limit the participant's ability to demonstrate treatment-related improvement in BCVA.\n5. Presence of an anterior chamber, sutured, or scleral-fixated intraocular lens.\n6. Presence of a multifocal or diffractive intraocular lens.\n7. Prior vitrectomy.\n8. Corneal refractive surgery.\n9. Descemet dettachment\n10. Minimally invasive glaucoma surgery (MIGS), intraocular pressure (IOP)- lowering implant (e.g., Durysta® or iDose®), or any incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage implant).","21 Years",{"count":53,"type":21},121,[55],"PHASE2","This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \\[mHCECs\\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.",[58,27,28,29,59,60,61,62,63,64,65,66],"Corneal Edema","Endothelial Corneal Dystrophy","Corneal Endothelial Decompensation","Corneal Endothelial Cell Loss","Corneal Endothelial Disorder","Corneal Endothelial Dystrophy 1","Endothelial Cell Loss, Corneal","Pseudophakic Bullous Keratopathy","Pseudophakic Bullous Keratopathy (PBK)",[68,69,70,28,27,71],"FECD","PBK","Corneal endothelial dysfunction","Corneal edema","NOT_YET_RECRUITING","2026-07-27",{"date":75,"type":34},"2026-07-29",{"date":77,"type":21},"2026-09",{"date":79,"type":21},"2028-02",{"name":81,"class":82},"Emmecell","INDUSTRY",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100594841","phase-2-dt-168-in-keratoplasty-patients-with-fuchs-endothelial-corneal-dystrophy-100594841","NCT07024693","DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy","A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty","Inclusion Criteria:\n\n* Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study.\n* ≥30 years of age (inclusive).\n* Documented diagnosis of FECD in the study eligible eye.\n* Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Any ocular or medical condition in the study eligible eye which is clinically significant or would confound study results or data interpretation.\n* Any clinically significant medical, nonmedical, and psychiatric disorders that could put the participant at higher risk for participation in the study, impair the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator.\n* Concurrent or anticipated need for treatment for FECD, eg, Muro 128 (2% or 5%) during the course of the study in the study eye. Provided the subject undergoes a washout of Muro drops for at least 24 hours prior to the Baseline Visit, they will not be excluded.\n* Concurrent or anticipated use of topical corticosteroids in the study eye.\n* Concurrent use with Rhopressa®, Rocklatan®, or any other ocular Rho Kinase inhibitor.\n* Known contraindication, allergy, or hypersensitivity to any of the treatments, anesthetics, or diagnostic agents or components thereof which may be used during the study.\n* Use of contact lenses in the study eye within 7 days prior to the Baseline Visit or planned use during the study.\n* Recent (within 30 days of the Screening Visit) or ongoing participation in any other investigational interventional clinical study.\n* Female participant is pregnant, planning a pregnancy, or breast-feeding.\n* Participant is unwilling to comply with the contraceptive requirements, as per protocol.","30 Years",{"count":93,"type":21},28,[55],"The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.",[97,27],"Fuchs Endothelial Corneal Dystrophy","2025-12-24",{"date":100,"type":34},"2025-12-29",{"date":102,"type":34},"2025-07-30",{"date":104,"type":21},"2026-12",{"name":106,"class":82},"Design Therapeutics, Inc.",2]